Date: 2013-04-11
Type of information: Presentation of results at a congress
phase: preclinical studies
Announcement: presentation of results at the Molecular Pattern Recognition Receptors meeting and the American Association for Cancer Research (
Company: Innate Pharma (France)
Product: IPH41
Action mechanism:
Disease: Sezary syndrome, lymphoma
Therapeutic area: Cancer - Oncology - Rare diseases
Country:
Trial details:
Latest
news: * On April 12, 2013, Innate Pharma, the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, has announces that new preclinical data for IPH41 proprietary program were presented at the Molecular Pattern Recognition Receptors meeting and the American Association for Cancer Research (AACR) annual meeting. Dr Sicard, Senior Director, R&D at Innate Pharma, presented a poster on IPH41 program: “Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T Cell Lymphomas”. The main conclusion is that in ex vivo patient samples, autologous NK cells can efficiently and selectively kill primary Sezary cells in presence of anti-KIR3DL2 antibodies as compared to alemtuzumab, a strongly lymphodepleting an ti-CD52 antibody. Innate Pharma’s anti-KIR3DL2 mAbs also showed activity in mice models of KIR3DL2+ tumor engraftment. In parallel, other antibodies were also developed as sensitive tools for the monitoring of KIR3DL2 as a biomarker in this patient population. KIR3DL2 is a receptor naturally expressed on some NK cells and minor subpopulations of T cells. It is also aberrantly overexpressed on subtypes of T lymphomas/leukemias, such as Sezary Syndrome (SS),transformed Mycosis Fungoides (tMF) and HTLV-1+ Adult T CellLeukemia.
Innate Pharma is in the process of selecting and validating the lead candidate for this program.
